NNC0165-1562 and Semaglutide Co-Administered for Weight Management in Overweight or Obese Patients

Obesity and overweight are chronic conditions associated with significant health risks, including cardiovascular disease and type 2 diabetes. While existing therapies like GLP-1 receptor agonists (e.g., semaglutide) have shown efficacy, there's a continuous need for novel agents or combination strategies to improve weight loss outcomes and patient response variability. This study explores a new compound, NNC0165-1562, in conjunction with semaglutide, aiming to identify enhanced treatment options for these prevalent metabolic conditions.

This randomized clinical trial investigates NNC0165-1562 co-administered with semaglutide versus semaglutide plus placebo in people who are overweight or obese. Participants receive 2 subcutaneous (SC) injections per week for 5 months, administered by a study nurse in a skin fold in the stomach. The study aims to assess the efficacy of NNC0165-1562 for weight control and its pharmacodynamic effects, with a total study duration of 7 months and 27 clinic visits.

This study description outlines the trial design and objectives but does not present any findings or numerical results. The primary goal is to investigate the efficacy and mechanism of action of NNC0165-1562 when combined with semaglutide for weight management. Specific outcomes related to weight loss, body composition, or metabolic parameters are not detailed in this preliminary information. The study aims to understand how the investigational medicines work in the body, but no data on GLP-1R activation, mTORC1 modulation, or other pathways are provided.